UK markets close in 1 hour 14 minutes

Newron Pharmaceuticals S.p.A. (0QOI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
1.5780+1.5780 (+405.31%)
As of 06:47PM GMT. Market open.
Full screen
Previous close2.4500
Open1.5780
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.5780 - 1.5780
52-week range1.5780 - 1.5780
Volume208
Avg. volumeN/A
Market cap21.269M
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-1.1430
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Change in Newron Board of Directors

    Newron Pharmaceuticals SpA / Key word(s): Personnel01-Dec-2021 / 17:46 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRMilan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today annou

  • EQS Group

    Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

    Newron Pharmaceuticals SpA / Key word(s): Financing18-Oct-2021 / 17:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 SIX Listing RulesMilan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peri

  • Business Wire

    Newron Announces Half-Year 2021 Results

    MILAN, September 16, 2021--Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) today announces its operational and financial results for the half-year ended June 30, 2021.